Leukemia Stem Cell-based Assay to Predict Relapse and Survival in AML Patients With MLL-Rearrangement
Summary
NIH's ClinicalTrials.gov has registered an observational study (NCT07537738) examining whether leukemia stem cell detection via multiparameter flow cytometry can predict relapse in acute myeloid leukemia patients with MLL-rearrangement. The study will detect leukemia stem cells alongside minimal residual disease monitoring using bone marrow samples. Participants are AML patients undergoing regular medical care who will have stem cell detection performed concurrently with their existing MRD testing protocols.
What changed
This document registers a new observational clinical study on ClinicalTrials.gov. The study aims to evaluate the predictive value of leukemia stem cell detection for relapse in AML patients with MLL-rearrangement, using multiparameter flow cytometry concurrent with minimal residual disease monitoring. The study carries no compliance obligations and does not create new regulatory requirements.
Affected parties—oncologists, hematologists, and clinical laboratories specializing in AML treatment—may wish to note this research for potential future implications on relapse prediction protocols. The study represents an observational data collection effort and does not impose reporting or operational requirements on healthcare providers beyond standard clinical care practices.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Observational NCT07537738 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:
• Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Conditions: Acute Myeloid Leukemia (AML), MLL Rearrangement
Interventions: Detection of leukemia stem cell using multiparameter flow cytometry
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.